Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers–Danlos Syndrome: The First Non‐European Cohort
American Journal of Medical Genetics Part A · 2026
DOI: 10.1002/ajmg.a.70178 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2026. Verfasst von Megumi Furuhata-Yoshimura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Celiprolol, Ehlers-Danlos Syndrome, Type IV, Ehlers-Danlos Syndrome, Collagen Type III. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Ministry of Health, Labour and Welfare of Japan, Japan Agency for Medical Research and Development, the Program for an Integrated Database of Clinical and Genomic Information.
Abstract (Originalsprache)
Vascular Ehlers–Danlos syndrome (vEDS) is a hereditary connective tissue disorder caused by heterozygous pathogenic variants in COL3A1 . European studies have shown that celiprolol may reduce the risk of life‐threatening vascular events, but outcomes in non‐European populations and the therapy's psychological impact remain unclear. We conducted a retrospective cohort study of individuals aged ≥ 20 years with genetically confirmed vEDS in a single referral center in Japan between 2000 and 2024. Clinical, molecular, and treatment data were obtained from medical records, and semi‐structured interviews were conducted with a subset of participants to assess patient experiences. Twenty‐six patients were included. The mean age at celiprolol initiation was 36.9 years, with a mean follow‐up of 96.6 months. All patients received celiprolol, and 61.5% reached the target dose (400 mg/day). One patient died of hepatic artery rupture; vascular events occurred in 11, while 14 remained event‐free. No significant associations were observed between vascular event occurrence and genotype or celiprolol dose. Interviews with 11 patients revealed that celiprolol use provided emotional reassurance and promoted a more proactive approach to disease management. Celiprolol therapy may reduce fatal vascular events in vEDS and have a positive psychological impact, though nonfatal vascular complications remain frequent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Pediatrics, Aizawa Hospital, Advanced Care Center, Matsumoto, Japan.
- Center for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan.
- Division of Clinical Sequencing, Shinshu University School of Medicine, Matsumoto, Japan.
- Research Center for Supports to Advanced Science, Shinshu University, Matsumoto, Japan.
- BioBank Shinshu, Shinshu University Hospital, Matsumoto, Japan.
ORCID-Profile: Tomoki Kosho
Förderung
- the Ministry of Health, Labour and Welfare of Japan
- Japan Agency for Medical Research and Development
- the Program for an Integrated Database of Clinical and Genomic Information
- Ministry of Health, Labour and Welfare
Zitieren
APA
Furuhata-Yoshimura, M., Yamaguchi, T., & Kosho, T. (2026). Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers–Danlos Syndrome: The First Non‐European Cohort. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.70178
Vancouver
Furuhata-Yoshimura M, Yamaguchi T, Kosho T. Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers–Danlos Syndrome: The First Non‐European Cohort. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.70178
BibTeX
@article{FuruhataYoshimura2026,
author = {Furuhata-Yoshimura, Megumi and Yamaguchi, Tomomi and Kosho, Tomoki},
title = {Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers–Danlos Syndrome: The First Non‐European Cohort},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
doi = {10.1002/ajmg.a.70178}
}
EUVIMED